Skip to main
XRAY
XRAY logo

DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target

DENTSPLY SIRONA (XRAY) Analyst Ratings

Based on 24 analyst ratings
Hold
Strong Buy 17%
Buy 25%
Hold 54%
Sell 4%
Strong Sell 0%

Bulls say

Dentsply Sirona is poised for positive financial growth, evidenced by a reported sales increase of 2.8% in Europe, alongside a 1.8% organic growth rate, indicating steady demand in the dental market. Additionally, the company's subsidiary, Wellspect Healthcare, demonstrated robust performance with $81 million in revenue, reflecting an 8.6% reported increase and 6.7% organic growth, suggesting strong product acceptance and market positioning. The firm is positioned to benefit from accelerating revenue growth projected in the mid-single digits, driven by improved market share in clear aligners, a recovering implants segment, and margin enhancements, which could contribute to faster earnings per share growth.

Bears say

Dentsply Sirona reported a substantial miss in its profitability, with adjusted EPS of $0.26 significantly lower than the expected $0.43, primarily due to disappointing revenue and increased operating expenses. The connected technology solutions segment experienced an 8.3% decline in revenue, highlighting ongoing challenges in revenue generation and gross margin performance, which fell short of consensus estimates. Moreover, the Byte shutdown led to a $62 million revenue loss, exacerbating the firm's already weak financial results, characterized by declining gross margins and rising operating costs across both SG&A and R&D.

DENTSPLY SIRONA (XRAY) has been analyzed by 24 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 25% recommend Buy, 54% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DENTSPLY SIRONA (XRAY) Forecast

Analysts have given DENTSPLY SIRONA (XRAY) a Hold based on their latest research and market trends.

According to 24 analysts, DENTSPLY SIRONA (XRAY) has a Hold consensus rating as of Jul 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DENTSPLY SIRONA (XRAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.